in one case and from 2+ to 0 in two cases. Nevertheless, the Her2 status of the metastatic tumors, as defined by FISH, did not change.

Conclusion: Our results suggest that Her2 status does not change in metastatic breast carcinoma. However, at present it is necessary to investigate the Her2 status of late metastases of breast carcinomas, because in many cases the Her2 status of the primary tumor is unknown.

Acknowledgement: This study was supported by the following grants: EAGC-Avon/2004, BIO-00014/2001, NKFP-1A/0023/2002.

406 Poster

Correlation between hormonal receptor levels and efficacy of hormonal therapy and chemotherapy in metastatic breast cancer

N. Snoj[1], T. Globokar[1], A. Sadikov[2], T. Cufer[1]. [1]*Institute of Oncology Ljubljana, Medical Oncology, Ljubljana, Slovenia;* [2]*Faculty of Computer and Information Science, Ljubljana, Slovenia*

Endocrine responsiveness defined by HR predicts the response to HT. It seems that the level of expression of HR correlates with the response to HT or even ChT. The aim of our analysis was to evaluate the response to first line HT and/or ChT for metastatic disease according to the HR levels in primary tumour.

Data of 260 patients (pts) treated for early breast cancer (BC) at Institute of Oncology Ljubljana from 1994 to 2001, that developed distant metastases in the median follow up time of 8.23 (4–11) years were reviewed. Response to HT was revived in 201 pts (aromatase inhibitors: 62%), and response to ChT in 187 postmenopausal pts (antracycline or taxane based: 57%). Response to HT was defined as clinical benefit (CB), including CR, PR and S for at least 3 months, response to ChT was defined as response rate (RR), including CR and PR. Progression free survival (PFS) was defined as time interval from the beginning of treatment till the date of confirmed disease progression or death due to BC. Response and PFS were analysed in subgroups of pts according to the imunohistochemical expression of ER, PR or both (rich ⩾90%, intermediate 10–90%, poor <10%). Kaplan Meier curves, log rank tests and STEPP curves were used for statistical analyses.

Response to HT was significantly different in subgroups of ER rich, ER intermediate and ER poor pts (65%, 57% and 27%, respectively; $p = 0.001$), however no difference between ER rich and ER intermediate groups was found ($p = 0.355$). Even higher differences in response were seen in subgroups of PR rich, PR intermediate and PR poor (75%, 59% and 40%, respectively; $p < 0.001$), with a trend for significant difference also between PR rich and PR intermediate groups ($p = 0.063$). When both receptors were taken into account, response in HT was higher in ER rich/PR rich compared to ER rich/PR poor subgroup of pts (81% vs. 54%; $p = 0.065$). In STEPP analysis all ER positive (⩾10%) pts responded equally well to HT, while the response continuously rose from PR 0% to PR 100%. Similar results for PFS were obtained in all subgroups. In our set of pts no significant differences in efficacy of ChT according to HR levels were confirmed.

We confirmed that the level of ER and PR predict the response to HT. In addition, we assume that ER positivity as such predicts a good response to HT, while in PR the level of receptor expression matters.

407 Poster

Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer

Y. Chin[1], D. Ravichandran[2], A. Makris[1]. [1]*Mount Vernon Hospital, Clinical Oncology, Northwood, United Kingdom;* [2]*Luton & Dunstable Hospital, Surgery, Luton, United Kingdom*

Aims: To assess the efficacy of the type 1, steroidal aromatase inactivator, Exemestane in post-menopausal women with locally advanced and/or metastatic breast cancer, who have previously received Tamoxifen and a non-steroidal third generation aromatase inhibitor (AI).

Methods and Materials: A retrospective analysis was performed on thirty one consecutive patients who commenced Exemestane 25 mg/day orally, from January 2000 to June 2005. Patients were required to have positive oestrogen receptor (ER) and/or progesterone receptor (PR) status or if unknown, had to have a clear response to previous hormonal treatment (n = 2). Previous hormonal treatment included Tamoxifen and a non-steroidal third generation AI (Anastrozole or Letrozole). Patients were followed up every 3 months until they developed clinical or radiological disease progression.

Results: Median patient age was 64 years (range 34–90 years). 12 patients had locally advanced disease alone, 19 had metastatic disease and 8 had both locally advanced and metastatic disease. Sites of metastatic disease include soft tissue (n = 4), lung (n = 4), liver (n = 8) and bone (n = 13). The average number of recurrences prior to starting Exemestane was three (range 1–6). 15 patients (48.4%) also had previous chemotherapy. There were 2 complete responses (CR), 4 partial responses (PR), 12 with stable disease (SD) and 12 with progressive disease (PD). The objective response rate (CR + PR) was 19.4% and the overall clinical benefit (CR + PR + SD ⩾24 weeks) was 41.9%. The median durations of objective response and overall clinical benefit were 18.3 months and 16.2 months respectively. One patient required discontinuation of Exemestane due to vertigo.

Conclusions: This data supports the anti-tumour activity of Exemestane 25 mg daily in patients with locally advanced and/or metastatic breast cancer who have been previously exposed to non-steroidal third generation AIs and Tamoxifen.

408 Poster

Phase II study with dose finding of Oral Vinorelbine in combination with Capecitabine as first-line chemotherapy of Metastatic Breast Cancer (MBC): Preliminary results of the phase II part of the study

F. Nolè[1], C. Catania[1], G. Sanna[1], R. Mattioli[2], D. Crivellari[3], P. Foa[4], G. Pinotti[5], D. Leroux[6], K. Imadalou[6], A. Goldhirsch[1]. [1]*European Institute of Oncology, Department of Medicine, Milan, Italy;* [2]*Ospedale santa Croce, Oncologia Medica, Fano, Italy;* [3]*Centro di Riferimento Oncologia, Oncologia Medica, Aviano, Italy;* [4]*Azienda Ospedaliera San Paolo, Oncologia Medica, Milan, Italy;* [5]*Universita Fondazione Macchi, U.O Oncologia Medica, varese, Italy;* [6]*Institut de Recherche Pierre-Fabre, Centre de développement Oncologie, Boulogne-Billancourt, France*

Several drugs are active in MBC. However, only few are available orally. The combination of Oral vinorelbine (VRL) and Capecitabine (Cape) has the advantage of its ease of use with no overlapping toxicity. Results of the phase I part of the study showed no interaction when both drugs are given concomitantly and established the following regimen: Oral VRL 60 mg/m^2 weekly with Cape 2000 mg/m^2/d from D1 to D14 every 3 weeks as one of the recommended dose for the phase II (F. Nolè; ASCO 2005, abstr 666). The present study investigated this weekly schedule to evaluate efficacy and tolerance of this combination in patients (pts) who had received no prior line of chemotherapy (CT) for MBC disease. Prior adjuvant chemotherapy with anthracycline and/or taxanes was allowed. Patients had at least one measurable lesion (WHO criteria) and KPS ⩾ 70%. The characteristics of the first 23 patients treated, were median age of 59 years, prior adjuvant chemotherapy in 78.3%, prior adjuvant hormonotherapy in 69.6%, disease free interval <2 years in 21.7%, visceral involvement in 82.6% (liver 60.9%, lung 47.8%). A total of 169 cycles were given with a median of 7 cycles. Median relative dose intensity (RDI) for Oral VRL and Cape were 72.6% and 85.3%, respectively. Neutropenia was the main side effects with grade 3–4 in 52.2% of pts and 12.5% of cycles, without any episode of complicated neutropenia. Grade 1 stomatitis were reported in 26.2% of pts and 10.7% of cycles, hand foot syndrome was observed in 39.1% of pts and 26.1% of cycles, with no grade 3. This combination demonstrated to be effective with RR of 47.8% [95% CI: 26.8–69.4] in the ITT population of 23 pts and 55% [95% CI: 31.5–76.9] in the 20 evaluable patients.

Conclusion: the combination of oral VRL 60 mg/m^2 weekly with Cape 2000 mg/m^2/d D1-D14 every 3 weeks demonstrated to be effective and safe in patients with MBC as first line chemotherapy. A total of 45 evaluable patients is planned in the study.

409 Poster

Continued use of goserelin to achieve ovarian function suppression in combination with a further aromatase inhibitor (exemestane) following prior treatment with anastrozole and/or tamoxifen in premenopausal women with oestrogen receptor positive advanced breast cancer

A. Agrawal, J. Robertson, L. Winterbottom, K. Cheung. *Nottingham City Hospital, Professorial Unit of Surgery, Nottingham, United Kingdom*

Introduction: The use of goserelin to achieve ovarian function suppression is a well-established therapeutic strategy in premenopausal women with oestrogen receptor positive (ER+) breast cancer. We have previously reported clinical/endocrine data of combined use of goserelin plus tamoxifen or anastrozole (a non-steroidal aromatase inhibitor) in premenopausal women with ER+ advanced breast cancer. We now report the clinical experience of continued use of goserelin given alongside exemestane (a steroidal aromatase inhibitor) in the same setting following prior treatment with anastrozole and/or tamoxifen.

Methods: Thirteen patients [median age: 45 (33–54) years] (advanced primary = 1, bone only = 6, bone + pleura = 4, bone + liver = 2) seen over a 32-month period were treated with goserelin 3.6 mg 4-weekly plus exemestane 25 mg daily as second to fourth line endocrine therapy. All patients had disease assessable by UICC criteria and received therapy for ⩾6 months (except for those who progressed prior).